Costs of Acute Headache Medication Use and Productivity Losses Among Patients with Migraine: Insights from Three Randomized Controlled Trials

Joshua K. Porter (), Gian Luca Di Tanna, Richard B. Lipton, Sandhya Sapra and Guillermo Villa
Additional contact information
Joshua K. Porter: Amgen (Europe) GmbH
Gian Luca Di Tanna: Amgen (Europe) GmbH
Richard B. Lipton: Albert Einstein College of Medicine
Sandhya Sapra: Amgen Inc
Guillermo Villa: Amgen (Europe) GmbH

PharmacoEconomics - Open, 2019, vol. 3, issue 3, No 15, 417 pages

Abstract: Abstract Background Migraine is associated with a substantial physical and emotional burden for patients. There is also a large economic burden associated with migraine, in terms of lost productivity and healthcare resource use. By reducing the number of monthly migraine days (MMD) experienced by patients, effective preventive treatments can reduce acute medication use and costs of lost productivity. Methods Patient level data from three erenumab clinical trials (NCT02456740, NCT02483585 and NCT02066415) were combined and migraine day frequencies were examined. The number of days per month on which patients used acute medication was estimated as a function of MMD. Productivity losses were estimated based on patient responses to the Migraine Disability Assessment questionnaire. Zero-inflated Poisson regression models were used to predict acute medication use and productivity losses per MMD. Results The results demonstrated that as MMD increased, use of acute medication also increased. Similarly, as MMD increased, loss of productivity (due to absenteeism and presenteeism) also increased. The relationship of MMD to both acute headache medication use and lost productivity was non-linear, with marginal outcomes increasing with frequency. Conclusions As MMD increased, acute medication use and productivity loss also increased, but the relationship was non-linear. Therefore, it is important that the distribution of MMD patients is accounted for when estimating the outcomes of migraine patients. By reducing the MMD experienced by patients, effective preventive agents may reduce the requirement for acute medication and also reduce productivity loss, which may translate into potential economic savings.

Date: 2019
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (2)

Downloads: (external link)
http://link.springer.com/10.1007/s41669-018-0105-0 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharmo:v:3:y:2019:i:3:d:10.1007_s41669-018-0105-0

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/41669

DOI: 10.1007/s41669-018-0105-0

Access Statistics for this article

PharmacoEconomics - Open is currently edited by Timothy Wrightson and Christopher Carswell

More articles in PharmacoEconomics - Open from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().